03.12.2023 D'vorah Graeser
Commercialization depends on deep knowledge of a system - and how it can be transformed into products that make the world a better place. But what happens if a researcher creates an entirely new system?
That’s the case with CRISPR. And universities are leading the way for industry to create products from this highly complex biological system.
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is adapted
from the naturally occurring “immune system” of bacteria. When bacteria are attacked by bacteriophages, which are a virus-like organism, the bacteria use CRISPR to incorporate part of the foreign genetic material into their own DNA.
Why CRISPR?
CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) is adapted from the naturally occurring “immune system” of bacteria. When bacteria are attacked by virus-like organisms, the bacteria use CRISPR to incorporate part of the foreign genetic material into their own DNA.
A CRISPR economy?
CRISPR is a technology rather than an industry and has two significant industrial applications: therapeutics and food cultivation, but these applications are still in the early stages of development. Therapeutic uses for CRISPR are particularly increasing in number, so recently, CRISPR has gone from being largely unregulated to becoming the subject of increased regulatory scrutiny.
CRISPR and Innovation
CRISPR’s lifeblood is innovation.
Despite the strong emerging patent portfolios of universities and companies, recent cases have brought to light the difficulty of crafting licensing agreements in a fast-moving field like CRISPR.
Valuation is particularly difficult for such a new technology. The potential is great - but the obstacles are many. So where should the valuation be set?
To get our full report about the potential and difficulties of CRISPR tech transfer for universities, click on this link.
To schedule some time to discuss valuing your new innovative idea, Click Here To Make An Appointment.
Looking forward to connecting,
